Forty Seven (Forty Seven) Risk Assessment

View and export this data going back to 2018. Start your Free Trial

What is Forty Seven Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Forty Seven is: No Data: Cannot be evaluated.

Competitive Comparison of Forty Seven's Risk Assessment

For the Biotechnology subindustry, Forty Seven's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Forty Seven's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forty Seven's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Forty Seven's Risk Assessment falls into.

Forty Seven (NAS:FTSV) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Forty Seven Risk Assessment Related Terms

Thank you for viewing the detailed overview of Forty Seven's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Forty Seven (Forty Seven) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forty Seven Inc (NAS:FTSV) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

1490 Oâ€™Brien Drive, Suite A, Menlo Park, CA, USA, 94025

Website

https://www.fortyseveninc.com

Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to activate macrophages and help the patients in their fight against cancer. It founded that blocking CD47, a key signaling molecule that is overexpressed on cancer cells renders tumors susceptible to macrophages. It is also preparing investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP-alpha antibody, is being developed for the treatment of cancer, and certain non-oncology conditions, including transplantation conditioning.

Executives

Dennis Henner	director	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Kristine M Ball	director	C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Ann D Rhoads	officer: Chief Financial Officer	4000 NORTH FIRST STREET, SAN JOSE CA 95134
Ian T Clark	director	SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Jeffrey W Bird	director	755 PAGE MILL RD STE A-200, PALO ALTO CA 94304-1005
Lightspeed General Partner X, L.p.	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Lightspeed Ultimate General Partner X, Ltd.	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Jeremy Liew	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Lightspeed Venture Partners X, L.p.	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Barry Eggers	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Peter Nieh	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Ravi Mhatre	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Stephen A Schwarzman	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Clarus Iii L.l.c.	10 percent owner	C/O THE BLACKSTONE GROUP L.P., 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Inc.	10 percent owner	345 PARK AVENUE, NEW YORK NY 10154